2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14353
    GSK-9772 928035-84-1 98%
    GSK-9772 is a Liver X Receptor (LXR) modulator of the N-phenyl tertiary amine class (NPTAs) with high affinity for LXR β ligand (IC50=30 nM). GSK-9772 has anti-inflammatory activity by binding to LXR, specifically by interacting with the region associated with the transcriptional repression function of the receptor, thereby inhibiting the expression of pro-inflammatory genes. GSK-9772 can be used in the study of inflammatory and neurodegenerative diseases.
    GSK-9772
  • HY-14477
    UPF-1035 370872-09-6 98%
    UPF-1035 is a selective PARP-2 inhibitor with an IC50 value of 0.15 μM. UPF-1035 increases CA1 pyramidal cell loss in hippocampal and has neuroprotective activity.
    UPF-1035
  • HY-14607
    Besipirdine hydrochloride 130953-69-4 98%
    Besipirdine (hydrochloride) is a potassium channel blocker with cholinergic and adrenergic activity. The cholinergic activity of Besipirdine (hydrochloride) involves stimulating phosphatidylinositol turnover and reducing potassium currents. The adrenergic activity of Besipirdine (hydrochloride) involves stimulating norepinephrine release, which is attributed to the inhibition of presynaptic α2-adrenergic receptors and the inhibition of norepinephrine uptake. Besipirdine (hydrochloride) may be used in research for Alzheimer's disease.
    Besipirdine hydrochloride
  • HY-14793
    Lensiprazine 327026-93-7 98%
    Lensiprazine is a potent dopamine D2 receptor (D2R) antagonist that acts as a serotonin reuptake inhibitor. Lensiprazine can be used to study bipolar disorder and schizophrenia.
    Lensiprazine
  • HY-14843
    Imagabalin 610300-07-7 98%
    Imagabalin (PD-0332334 free base) is an active compound with activity for studying neurological diseases. The synthesis of imagabalin involves the reaction of 3-methylvaleric acid and Meldrum acid. During the synthesis of imagabalin, an acyl chloride intermediate species, 3-methylvaleryl chloride, was revealed for the first time. The synthesis of imagabalin also provided new information about the reaction mechanism, indicating that 3-methylvaleric anhydride is an important intermediate.
    Imagabalin
  • HY-14856
    Atagabalin 223445-75-8 98%
    Atagabalin (PD 0200390) is a selective GABA (gamma-aminobutyric acid) receptor agonist with antianxiety and sedative effects. Atagabalin enhances the activity of the GABA receptor by binding to the α2δ subunit of the GABA receptor, thereby increasing the GABA mediated inhibition. This enhancement results in reduced excitability of neurons, helping to reduce anxiety and improve sleep. Atagabalin can be used to study neuropsychiatric disorders, anxiety or sleep disorders.
    Atagabalin
  • HY-14958
    Pardoprunox 269718-84-5 98%
    Pardoprunox (SLV-308) is a partial dopamine D2 and D3 receptor partial agonist and a serotonin 5-HT1A receptor agonist, with pEC50s of 8, 9.2, and 6.3, respectively.
    Pardoprunox
  • HY-15238
    ST-836 1148156-63-1 98%
    ST-836 is a dopamine receptor ligand; Antiparkinsonian agent.
    ST-836
  • HY-15470
    GW791343 trihydrochloride 309712-55-8 98%
    GW791343 trihydrochloride is a potent human P2X7 receptor negative allosteric modulator (exhibits species-specific activity), produces a non-competitive antagonist effect on human P2X7 receptor, with a pIC50 of 6.9-7.2. GW791343 trihydrochloride can enhance ATP rhythm. GW791343 trihydrochloride can be used in study of neurological disease.
    GW791343 trihydrochloride
  • HY-15543
    CP-809101 479683-64-2 98%
    CP-809101 is a potent and highly selective 5-HT2C receptor agonist, with pEC50s of 9.96, 7.19 and 6.81 M for human 5HT2C, 5HT2B and 5HT2A receptor. CP-809101 inhibits conditioned avoidance responding in rats and antagonizes both PCP (phencyclidine hydrochloride)- and d-amphetamine-induced hyperactivity. CP-809101 also reduces food and nicotine dependence in rats, can be used in studies of antipsychotic and nicotine dependence.
    CP-809101
  • HY-15800
    CZC-25146 hydrochloride 1330003-04-7 98%
    CZC-25146 hydrochloride is a potent LRRK2 inhibitor with IC50 values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 hydrochloride inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 hydrochloride prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 hydrochloride exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 hydrochloride can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 hydrochloride can be used to research Parkinson's disease and liver diseases.
    CZC-25146 hydrochloride
  • HY-16923
    Crobenetine 221019-25-6 98%
    Crobenetine (BIII-890), a benzomorphan derivative, is a potent, selective, and highly use-dependent Na+ channel blocker. Crobenetine displaces [3H]BTX from site 2 of the Na+ channel (IC50=49 nM) in rat brain synaptosomes, yet exhibits only low binding affinity for other receptors and ion channels. Crobenetine protects brain tissue from the deleterious effects of focal cerebral ischemia in rodents.
    Crobenetine
  • HY-17033
    Rocuronium 143558-00-3 98%
    Rocuronium (Org-9426) is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia.
    Rocuronium
  • HY-18039
    WAY-361789 1040718-40-8 98%
    WAY-361789 (SEN15924) is an orally active agonist for α7 nicotinic acetylcholine receptor (α7 nAChR) with an EC50 of 0.18 μM. WAY-361789 improves the cognitive function, exhibits potential in ameliorating Alzheimer’s Disease and schizophrenia.
    WAY-361789
  • HY-18101
    BD-1063 150208-28-9 98%
    BD-1063 is a selective σ-1 receptor antagonist with inhibitory activity against TRPC5 and TRPM3. BD-1063 exerts anti-hyperalgesic and anti-allodynic effects by inhibiting sustained calcium influx mediated by TRPC5 and TRPM3, and reverses the effects of Carrageenan (HY-125474). BD-1063 also significantly reduces excessive ethanol self-administration behavior. BD-1063 is widely used in studies on the mechanisms underlying neuropathic pain, inflammatory hyperalgesia, and alcohol abuse and dependence.
    BD-1063
  • HY-18112
    AZ-4217 1383846-83-0 98%
    AZ-4217 is an inhibitor for β-site amyloid precursor protein cleavage enzyme 1 (BACE1), with IC50 of 160 pM in human SH-SY5Y cells. AZ-4217 reduces amyloid deposition in Tg2576 mouse models, and is used for Alzheimer’s Disease research.
    AZ-4217
  • HY-18297
    ASK1-IN-5 1124381-69-6 98%
    ASK1-IN-5 (S-99) is an inhibitor of apoptosis signal-regulated kinase 1 (ASK1) and is useful in the study of autoimmune and neurodegenerative diseases.
    ASK1-IN-5
  • HY-18332
    Amitifadine 410074-73-6 98%
    Amitifadine (DOV-21947; EB-1010) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), with IC50s of 12, 23, 96 nM for serotonin, norepinephrine and dopamine in HEK 293 cells , respectively.
    Amitifadine
  • HY-18334
    GSK-2262167 sodium 1165923-54-5 98%
    GSK-2262167 sodium is a selective S1P1 receptor agonist. GSK-2262167 sodium is used for research on inflammatory and immune diseases.
    GSK-2262167 sodium
  • HY-19005
    GYKI-32887 78463-86-2 98%
    GYKI-32887 is a dopaminergic agonist that can reduce the motor activity levels in rats.
    GYKI-32887
Cat. No. Product Name / Synonyms Application Reactivity